Revive Therapeutics Stock Today
| RVVTF Stock | USD 0.01 0.0009 8.18% |
PerformanceWeakest
| Odds Of DistressSmall
|
Revive Therapeutics is trading at 0.0101 as of the 1st of October 2025. This is a 8.18 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0101. Revive Therapeutics has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of July 2025 and ending today, the 1st of October 2025. Click here to learn more.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Revive Therapeutics is traded on OTC Exchange in the United States.. The company has 353.56 M outstanding shares. More on Revive Therapeutics
Moving against Revive Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Revive Pink Sheet Highlights
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Revive Therapeutics [RVVTF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.1 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Revive Therapeutics's market, we take the total number of its shares issued and multiply it by Revive Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Revive Therapeutics classifies itself under Pharmaceuticals sector and is part of Health Care industry. The entity has 353.56 M outstanding shares.
Revive Therapeutics has accumulated about 5.29 M in cash with (13.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Revive Therapeutics Probability Of Bankruptcy
Ownership AllocationRevive Therapeutics owns a total of 353.56 Million outstanding shares. Roughly 95.1 pct. of Revive Therapeutics outstanding shares are held by general public with 2.48 % owned by insiders and only 2.42 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Revive Ownership Details
Revive Therapeutics Risk Profiles
| Mean Deviation | 5.4 | |||
| Standard Deviation | 7.59 | |||
| Variance | 57.59 | |||
| Risk Adjusted Performance | (0.01) |
Revive Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Revive Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Revive Therapeutics Corporate Management
| Michael Frank | Chairman CEO | Profile | |
| Derrick Welsh | COO Pharma | Profile | |
| Onesmo Mpanju | Chief Consultant | Profile | |
| ACIS BComm | Chief Officer | Profile | |
| McKee MD | Chief Consultant | Profile |
Other Information on Investing in Revive Pink Sheet
Revive Therapeutics financial ratios help investors to determine whether Revive Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.